The abstract is read at the publisher; the summary is JClub's.
In a multicenter European NSCLC cohort (n=28,244), TP53 Y220C was found in 195 patients (0.7%), with prevalence higher than solid tumors overall (0.4%).
- Why it matters: The PYNNACLE trial suggested benefit for Y220C reactivation, but NSCLC-specific clinicogenomic context was unclear, limiting how to select patients for future targeted studies.
- What they did: Investigators retrospectively analyzed Next Generation Sequencing data from NSCLC patients across European institutions, quantifying TP53 Y220C frequency and co-mutations and testing associations with clinical and molecular features.
- The result: TP53 Y220C showed no significant links to gender, smoking status, histology, or stage, but was more common in EGFR-mutant tumors (1.7% vs. 0.7%; p=0.029) and 17.0% had a second TP53 mutation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.